What remains concerning is the apparent lack of enthusiasm for the use of PPIs in patients on low-dose aspirin despite this significant GI risk. de Jong et al. (7) reported on data from 120 Dutch primary care centers looking at patients 18 years and older who were regularly prescribed low-dose ASA. They found that 26% of patients on low-dose aspirin (3,213 of 12,343) were considered at increased risk of GI complications but that the concomitant use of PPIs was only in 46% of these patients. In the low-dose aspirin group of the COGENT, omeprazole therapy was associated with 1.9% absolute risk reduction in primary upper GI events at 180 days (1.2% vs. 3.1%), which was comparable to the 1.7% absolute risk reduction for the high- The COGENT investigators should be commended for bringing this important GI safety issue to the forefront because it has been long overshadowed by both the concern about a PPI-clopidogrel interaction and by the false sense of security in the belief that low-dose aspirin, as opposed to high-dose aspirin, does not warrant a GI protective strategy.
